Clinical Edge Journal Scan

Ultrasound Assessment of Clinically Healthy Nails Can Aid in PsA Diagnosis


 

Key clinical point: Ultrasound assessment showed reduced thickness of nail bed and adjacent skin in clinically healthy nails of patients with psoriatic arthritis (PsA) than in control individuals without the disease.

Major finding: Ultrasound identified more morphological changes in the clinically healthy nails of patients with PsA vs control individuals (16.89% vs 3.33%; P = .03), along with significantly lower thickness of nail bed (1.77 mm vs 2.07 mm; P = .027) and adjacent skin (2.26 mm vs 2.59 mm; P = .003). Also, the adjacent skin thickness was positively correlated with tender joint count (correlation coefficient, 0.46; P = .03), suggesting that it can be used as a disease activity indicator.

Study details: This cross-sectional study involved the ultrasound assessment of clinically healthy nails in 22 patients with PsA (219 nails) who were compared with 21 control individuals without PsA (210 nails).

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Mahmoud I, Rouached L, Rahmouni S, et al. Ultrasound assessment of psoriatic arthritis patients with clinically normal nails and evaluation of its correlation with the disease activity: A case-control study . J Ultrasound Med. Published online April 18, 2024. Source

Recommended Reading

Commentary: Comparisons Among PsA Therapies, May 2024
MDedge Rheumatology
Poor Use of ICD-10 Rheumatology Codes Suggests New Approach Needed for ICD-11 Adoption
MDedge Rheumatology
Secukinumab Safe and Effective in Challenging-to-Treat Patients With PsA
MDedge Rheumatology
Risankizumab Shows Long-Term Efficacy in PsA Regardless of Baseline Characteristics
MDedge Rheumatology
Elevated Risk for PsA in Patients With Psoriasis and Arthralgia
MDedge Rheumatology
Study Identifies Risk Factors for Development of Psoriasis To Clinical PsA
MDedge Rheumatology
Real-World Study Confirms Short-Term Efficacy of Guselkumab in PsA
MDedge Rheumatology
Real-World Evidence Confirms Efficacy of Ixekizumab in PsA
MDedge Rheumatology
Can Eta Protein Distinguish PsA from RA?
MDedge Rheumatology
Meta-Analysis Confirms Efficacy and Safety of Bimekizumab in PsA
MDedge Rheumatology